Patient attitude towards lecanemab: results from a survey within the European Alzheimer's disease consortium (EADC), the German memory clinic network (DNG) and Austrian memory centers

INTRODUCTIONLecanemab approval was long pending in the EU but has now been granted. European patient attitudes towards anti-amyloid therapies are insufficiently assessed and reported. METHODSWe conducted an anonymous, multicenter survey across European memory clinics targeting patients with early symptomatic AD. A standardized questionnaire with four yes/no questions assessed attitudes toward lecanemab treatment and approval, including in the context of APOE4 homozygosity. RESULTSAmong 281 participants, endorsement rates were high for both individual treatment (82%) and general EU approval (92%). While still high, support was lower for treatment and approval in the context of APOE4 homozygosity (61% and 77%). Support for approval for APOE4 homozygotes declined after regulatory recommendations excluded this group. Results were consistent across European regions. DISCUSSIONStrong support for access to lecanemab reflects the significant patient need for disease-modifying therapies and underscores the importance of considering patient perspectives in regulatory decision-making.